Maze Therapeutics officer sells 9,705 shares at $26

Maze Therapeutics’ President, R&D & CMO sold 9,705 common shares under a pre-arranged Rule 10b5-1 trading plan.

Available on EDGAR 09/08/2026 - 04:21 PM EDT Accepted by SEC EDGAR 09/08/2026 - 04:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) reported that Harold Bernstein, President, R&D & Chief Medical Officer, sold 9,705 shares of common stock on September 4, 2026 in a market transaction at a weighted average price of $26.2238 per share. The sale was made under a Rule 10b5-1 trading plan adopted on September 29, 2025, and Bernstein now holds no shares directly after this transaction.

Insider Trade Summary 10b5-1

Net Seller: 9,705 shares

Net Sell 1 txn

Insider Bernstein Harold

Role President, R&D & CMO

Sold 9,705 shs ($255K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	9,705	$26.2238	$255K

Holdings After Transaction: Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.42 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 9,705 shares Weighted average sale price: $26.2238 per share Sale price range: $25.77 to $26.42 per share +2 more

5 metrics

Shares sold 9,705 shares Common stock sold by Harold Bernstein on September 4, 2026

Weighted average sale price $26.2238 per share Average price for the September 4, 2026 sale

Sale price range $25.77 to $26.42 per share Range of prices for multiple sale transactions on September 4, 2026

Shares held directly after transaction 0 shares Direct holdings of Harold Bernstein after the reported sale

Rule 10b5-1 plan adoption date September 29, 2025 Date Harold Bernstein adopted the trading plan used for this sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, multiple transactions

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

multiple transactions financial

"These shares were sold in multiple transactions at prices ranging from $25.77 to $26.42 per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MAZE report for Harold Bernstein?

Maze Therapeutics reported that Harold Bernstein sold 9,705 shares of its common stock on September 4, 2026 in a market transaction at a weighted average price of $26.2238 per share.

Was the MAZE insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sale was effected pursuant to a Rule 10b5-1 trading plan that Harold Bernstein adopted on September 29, 2025.

How many MAZE shares did Harold Bernstein hold after this transaction?

After selling 9,705 shares of Maze Therapeutics common stock, the filing reports that Harold Bernstein held 0 shares directly.

What price range were the MAZE shares sold at in this Form 4?

The Form 4 notes that the weighted average price was $26.2238 per share, and that the shares were sold in multiple transactions at prices ranging from $25.77 to $26.42 per share.

What role does the insider in this MAZE Form 4 hold?

The reporting person, Harold Bernstein, serves as President, R&D & Chief Medical Officer of Maze Therapeutics, Inc., according to the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bernstein Harold

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D & CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2026		S(1)		9,705	D	$26.2238(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.42 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Courtney Phillips, as attorney-in-fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)